Effects of a new 1,2,3-thiadiazole containing hydrazone antimycobacterial agent on serum and liver biochemical parameters in female mice

References

• Abdel-Ghaffar, O., et al. 2018. Ameliorative effect of rutin against isoniazid-induced alterations in certain hematological and biochemical parameters of albino rats. International Journal of Pharmacology, 14, 39–51.
   Web of Science ®Google Scholar
• Angelova, V.T., et al. 2019. New indole and indazole derivatives as potential antimycobacterial agents. Medicinal Chemistry Research, 28(4), 485–497.
   Web of Science ®Google Scholar
• Angelova, V.T., et al. 2017a. Synthesis, antimycobacterial activity and docking study of 2-aroyl-[1] benzopyrano [4, 3-c] pyrazol-4 (1H)-one derivatives and related hydrazide-hydrazones. Bioorganic & Medicinal Chemistry Letters, 27, 2996–3002.
   PubMed Web of Science ®Google Scholar
• Angelova, V.T., et al. 2017b. Antimycobacterial activity of novel hydrazide-hydrazone derivatives with 2H-chromene and coumarin scaffold. Bioorganic & Medicinal Chemistry Letters, 27, 223–227.
   PubMed Web of Science ®Google Scholar
• Attri, S., et al. 2000. Isoniazid–and rifampicin–induced oxidative hepatic injury–protection by N–acetylcysteine. Human & Experimental Toxicology, 19, 517–522.
   PubMed Web of Science ®Google Scholar
• Beteck, R.M., et al. 2019. Quinolone-isoniazid hybrids: Synthesis and preliminary in vitro cytotoxicity and anti-tuberculosis evaluation. MedChemComm, 10(2), 326.
   PubMed Web of Science ®Google Scholar
• Bhadauria, S., et al. 2007. Isoniazid induces oxidative stress, mitochondrial dysfunction and apoptosis in Hep G2 cells. Cellular and Molecular Biology (Noisy-le-Grand, France), 53, 102–114.
   PubMed Web of Science ®Google Scholar
• Boelsterli, U.A., and Lee, K.K., 2014. Mechanisms of isoniazid‐induced idiosyncratic liver injury: emerging role of mitochondrial stress. Journal of Gastroenterology and Hepatology, 29(4), 678–687.
   PubMed Web of Science ®Google Scholar
• Bump, E.A., Taylor, Y.C., and Brown, J.M., 1983. Role of glutathione in the hypoxic cell cytotoxicity of misonidazole. Cancer Research, 43(3), 997–1002.
   PubMed Web of Science ®Google Scholar
• Chen, X., et al. 2011. The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice. European Journal of Pharmacology, 659(1), 53–60.
   PubMed Web of Science ®Google Scholar
• Chen, Y., et al. 2013. Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicology and Applied Pharmacology, 273(3), 435–441.
   PubMed Web of Science ®Google Scholar
• Chowdhury, A., et al. 2001. Induction of oxidative stress in antitubercular drug-induced hepatotoxicity. Indian Journal of Gastroenterology, 20(3), 97–100.
   Google Scholar
• Control and Prevention. 2010. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004–2008. MMWR. Morbidity and Mortality Weekly Report, 59, 224.
   PubMedGoogle Scholar
• De Logu, A., et al. 2002. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 49(2), 275–282.
   PubMed Web of Science ®Google Scholar
• Eldehna, W., et al. 2015. Design, synthesis and antitubercular activity of certain nicotinic acid hydrazides. Molecules, 20(5), 8800–8815.
   PubMed Web of Science ®Google Scholar
• Ergul, Y., et al. 2010. Effect of vitamin C on oxidative liver injury due to isoniazid in rats. Pediatrics International, 52(1), 69–74.
   PubMed Web of Science ®Google Scholar
• Fratz-Berilla, E.J., et al. 2017. Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four x-linked protoporphyria patients. Biochimica et Biophysica Acta (Bba) - Molecular Basis of Disease, 1863(2), 428–439.
   PubMed Web of Science ®Google Scholar
• Georgieva, N., and Gadjeva, V., 2002. Isonicotinoylhydrazone analogs of isoniazid: relationship between superoxide scavenging and tuberculostatic activities. Biochemistry (Moscow), 67(5), 588–591.
   PubMed Web of Science ®Google Scholar
• Hearn, M.J., and Cynamon, M.H., 2004. Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base. Journal of Antimicrobial Chemotherapy, 53(2), 185–191.
   PubMed Web of Science ®Google Scholar
• Jeyaraman, P., Alagarraj, A., and Natarajan, R., 2019. In silico and in vitro studies of transition metal complexes derived from curcumin–isoniazid Schiff base. Journal of Biomolecular Structure and Dynamics, 1–15 In Press.
   Web of Science ®Google Scholar
• Johansen, M.D., Kremer, L., and Kumar, V., 2019. Design, synthesis, anti‐mycobacterial and cytotoxic evaluation of C‐4 functionalized 1, 8‐naphthalimide‐heterocyclic hydrazide conjugates. Chemical Biology & Drug Design, 94(1), 1300–1305.
   PubMed Web of Science ®Google Scholar
• Kester, N., 1971. Isoniazid hepatotoxicity fact or fantasy. JAMA, 217(5), 699–699.
   PubMed Web of Science ®Google Scholar
• Khan, S., et al. 2019. Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence. Bioscience Reports, 39(1), BSR20180845.
   PubMedGoogle Scholar
• Loulergue, P., Mir, O., and Dhote, R., 2007. Pure red blood cell aplasia and isoniazid use. Emerging Infectious Diseases, 13(9), 1427–1428.
   PubMed Web of Science ®Google Scholar
• Lu, J., et al. 2014. Investigation of isoniazid DILI mechanisms in human induced pluripotent stem cell derived hepatocytes. Drug Metabolism Reviews, 45, 177–177.
   Web of Science ®Google Scholar
• Mahmoud, A.M., Germoush, M.O., and Soliman, A.S., 2014. Berberine attenuates isoniazid-induced hepatotoxicity by modulating peroxisome proliferator-activated receptor gamma, oxidative stress and inflammation. International Journal of Pharmacology, 10(8), 451–460.
   Web of Science ®Google Scholar
• Mak, A., 2018. Investigation of the mechanism of idiosyncratic drug-induced liver injury by immune system modulation. Thesis. University of Toronto (Canada).
   Google Scholar
• Martins, F., et al. 2013. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB. Current Pharmaceutical Design, 20(27), 4427–4454.
   Web of Science ®Google Scholar
• Mathew, B., et al. 2015. Hydrazones as a privileged structural linker in antitubercular agents: a review. Infectious Disorders – Drug Targets), 15, 76–88.
   PubMedGoogle Scholar
• Meng, X., et al. 2015. Auto-oxidation of isoniazid leads to isonicotinic-lysine adducts on human serum albumin. Chemical Research in Toxicology, 28(1), 51–58.
   PubMed Web of Science ®Google Scholar
• Metushi, I.G., and Uetrecht, J., 2014. Isoniazid-induced liver injury and immune response in mice. Journal of Immunotoxicology, 11(4), 383–392.
   PubMed Web of Science ®Google Scholar
• Metushi, I.G., et al. 2014. Paradoxical attenuation of autoimmune hepatitis by oral isoniazid in wild-type and N-acetyltransferase–deficient mice. Drug Metabolism and Disposition, 42(6), 963–973.
   PubMed Web of Science ®Google Scholar
• Metushi, I.G., Nakagawa, T., and Uetrecht, J., 2012. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chemical Research in Toxicology, 25(11), 2567–2576.
   PubMed Web of Science ®Google Scholar
• Negi, V., et al., 2012. Biological activities of hydrazone derivatives in the new millennium. International Journal of Pharmaceutical Chemistry, 4, 100–109.
   Google Scholar
• Pal, R., et al. 2008. Isoniazid-rifampicin induced lipid changes in rats. Clinica Chimica Acta, 389(1–2), 55–60.
   PubMed Web of Science ®Google Scholar
• Piso, R.J., Kriz, K., and Desax, M.-C., 2011. Severe isoniazid related sideroblastic anemia. Hematology Reports, 3(1), 2–e2.
   PubMedGoogle Scholar
• Polizio, A.H., and Peña, C., 2005. Effects of angiotensin II type 1 receptor blockade on the oxidative stress in spontaneously hypertensive rat tissues. Regulatory Peptides, 128, 1–5.
   PubMed Web of Science ®Google Scholar
• Saad, E.I., et al. 2010. Role of oxidative stress and nitric oxide in the protective effects of α-lipoic acid and aminoguanidine against isoniazid–rifampicin-induced hepatotoxicity in rats. Food and Chemical Toxicology, 48(7), 1869–1875.
   PubMed Web of Science ®Google Scholar
• Shah, I., et al. 2019. Pharmacokinetics of isoniazid in Indian children with tuberculosis on daily treatment. The International Journal of Tuberculosis and Lung Disease, 23(1), 52–57.
   PubMed Web of Science ®Google Scholar
• Shukla, A., et al. 2014. Pure red cell aplasia: a rare complication of isoniazid therapy. Indian Journal of Hematology and Blood Transfusion, 30(S1), 36.
   PubMedGoogle Scholar
• Sodhi, C., et al. 1997. Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in young rats. Drug and Chemical Toxicology, 20(3), 255–269.
   PubMed Web of Science ®Google Scholar
• Tasduq, S.A., et al. 2007. Potentiation of isoniazid‐induced liver toxicity by rifampicin in a combinational therapy of antitubercular drugs (rifampicin, isoniazid and pyrazinamide) in Wistar rats: a toxicity profile study. Hepatology Research, 37(10), 845–853.
   PubMed Web of Science ®Google Scholar
• Yu, A.-M., and Zhong, X-b., 2016. Advanced knowledge in drug metabolism and pharmacokinetics. Acta Pharmaceutica Sinica. B, 6(5), 361
   PubMed Web of Science ®Google Scholar